Processes Patents (Class 536/18.5)
  • Patent number: 10508081
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: December 17, 2019
    Assignee: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • Patent number: 10301343
    Abstract: According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4?-epi-feudomycin, which are typical impurities possibly contained in 4?-epi-daunorubicin as a starting material, by using an organic acid salt of 4?-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 28, 2019
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Kenichiro Mori, Takuto Umezu, Takahisa Maruyama, Sojiro Shiokawa
  • Patent number: 10030040
    Abstract: The invention relates to processes for preparing (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside and compositions comprising the same.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: July 24, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Melpo Christofidou-Solomidou, Kyriacos C. Nicolaou, Roman A. Valiulin, Nicholas Simmons, Philipp M. Heretsch
  • Patent number: 9808790
    Abstract: Disclosed are catalysts comprised of platinum and gold. The catalysts are generally useful for the selective oxidation of compositions comprised of a primary alcohol group and at least one secondary alcohol group wherein at least the primary alcohol group is converted to a carboxyl group. More particularly, the catalysts are supported catalysts including particles comprising gold and particles comprising platinum, wherein the molar ratio of platinum to gold is in the range of about 100:1 to about 1:4, the platinum is essentially present as Pt(0) and the platinum-containing particles are of a size in the range of about 2 to about 50 nm. Also disclosed are methods for the oxidative chemocatalytic conversion of carbohydrates to carboxylic acids or derivatives thereof. Additionally, methods are disclosed for the selective oxidation of glucose to glucaric acid or derivatives thereof using catalysts comprising platinum and gold. Further, methods are disclosed for the production of such catalysts.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: November 7, 2017
    Assignee: Rennovia Inc.
    Inventors: Vincent J. Murphy, James Shoemaker, Guang Zhu, Raymond Archer, George Frederick Salem, Eric L. Dias
  • Patent number: 9790243
    Abstract: The present description refers to photocleavable compounds which can be used as a photocleavable linker in order to link two biomolecules, such as oligonucleotides and peptides. The present description further refers to a method for the synthesis of said photocleavable compounds.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: October 17, 2017
    Assignee: Ventana Medical Systems, Inc.
    Inventor: Klaus-Peter Stengele
  • Patent number: 9700061
    Abstract: A milk ingredient is enriched in polar lipids, in particular in phospholipids and in sphingolipids, in which the percentage of phospholipids is greater than 10% by weight, relative to the weight of solids of the ingredient, and a method obtains the same starting from pasteurized cream and is used in food and/or pharmaceutical products.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: July 11, 2017
    Assignee: S.A. CORMAN
    Inventors: Daniel Dalemans, Christophe Blecker, Pascal Bodson, Sabine Danthine, Claude Deroanne, Michel Paquot
  • Patent number: 9169284
    Abstract: This invention relates to the miniaturization of radiosyntheses onto microfabricated devices, and in particular to use of microfabricated devices for radiosynthesis, isolation, and analysis of radiotracers for use in Positron Emission Tomography (PET).
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: October 27, 2015
    Assignee: Hammersmith Imanet Limited
    Inventors: Frank Brady, Sajinder Kaur Luthra, James Millar Gillies, Nicholas Toby Jeffrey
  • Publication number: 20150140610
    Abstract: A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Adrian Ortiz, Tamas Benkovics, Zhongping Shi, Prashant P. Deshpande, Zhiwei Guo, David R. Kronenthal, Chris Sfouggatakis
  • Publication number: 20150099870
    Abstract: Provided are methods for the preparation of glycosylation products, including those represented by formula I: Sugar-O—R???I comprising the step of combining R?—OH, a glycosyl sulfide glycosyl donor (“thioglycoside donor”), a hypervalent iodine alkyl-transfer activating reagent, and a base. In an embodiment, the hypervalent iodine alkyl-transfer activating reagent is (phenyl(trifluoroethyl)iodonium triflimide).
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Clay S. Bennett, An-Hsiang A. Chu
  • Patent number: 8987430
    Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: March 24, 2015
    Assignee: Reliable Biopharmaceutical Corporation
    Inventors: Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
  • Patent number: 8987437
    Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 24, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard Hung Chiu Yu, Brandon Heath Brown, Richard P. Polniaszek, Benjamin R. Graetz, Keiko Sujino, Duong Duc-Phi Tran, Alan Scott Triman, Kenneth M. Kent, Steven Pfeiffer
  • Patent number: 8981079
    Abstract: A chlorinating agent such as a chloroiminium species is used to remove or neutralize tertiary acetamide present as a contaminant in a tertiary formamide solvent. Tertiary formamide solvent purified or treated in this manner can be used as a reaction vehicle for the chlorination of sucrose-6-acylates, thereby improving the yields of the desired sucralose-6-acylate (an intermediate in the production of sucralose).
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: March 17, 2015
    Assignee: Tate & Lyle Technology Limited
    Inventors: James Edwin Wiley, Jr., Mohamad R. Jaber
  • Publication number: 20150065700
    Abstract: Provided is a method for preparing 3-O-benzyl-1,2-O-isopropylidene-?-L-idofuranose, which comprises: (1) protecting hydroxyl of 3-O-benzyl-1,2-O-isopropylidene-?-D-glucofuranose (III) by benzoyl and methylsulfonyl to obtain 6-O-benzoyl-3-O-benzyl-1,2-O-isopropylidene-5-O-methylsulfonyl-?-D-glucofuranose (V); (2) subjecting compound (V) to a cyclization reaction under an alkaline condition to obtain 5,6-epoxy-3-O-benzyl-1,2-O-isopropylidene-?-L-idofuranose (VI); and (3) subjecting compound (VI) to a ring-opening reaction to obtain 3-O-benzyl-1,2-O-isopropylidene-?-L-idofuranose.
    Type: Application
    Filed: February 22, 2013
    Publication date: March 5, 2015
    Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Yanghui Guo, Hegeng Wei, Junhui Zhou, Yingqiu Wu, Yue Zhang, Hua Bai, Liang He, Yili Ding
  • Publication number: 20150038689
    Abstract: Provided are methods for the efficient stereoselective formation of glycosidic bonds, without recourse to prosthetic or directing groups.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 5, 2015
    Inventors: Clay S. Bennett, John P. Issa, Dina Lloyd
  • Patent number: 8940880
    Abstract: The present invention concerns a process for the preparation of the compound of formula The compound of formula (1) is the key intermediate in the synthesis of some antibacterial agents of the triamilide class, such as Tulathromycin, useful to treat bacterial and protozoa infections.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: January 27, 2015
    Assignee: Novartis AG
    Inventors: Rafael Garcia, Oriol Martorell, Albert Codony
  • Publication number: 20150025030
    Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.
    Type: Application
    Filed: June 8, 2013
    Publication date: January 22, 2015
    Applicant: ZHEJIANG YONGNING PHARMACEUTICAL CO LTD
    Inventors: Fengqi Ye, Ben Cai, Min Lu, Yongling Chen
  • Patent number: 8937168
    Abstract: The invention provides methods of purifying rebaudioside A from a mixture comprising glycosides of the plant Stevia rebaudiana. The methods of the invention are useful for preparing highly pure rebaudioside A compositions from crude Stevia starting compositions that are typically considerably lower in rebaudioside A concentration. The highly pure rebaudioside A compositions are useful as non-caloric sweeteners in edible or chewable compositions such as food, beverages, medicine, candy, chewing gum, and the like.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: January 20, 2015
    Assignee: Cargill, Incorporated
    Inventors: Jeffrey C. Evans, John J. Hahn, Allan S. Myerson, Timothy Oolman, Troy A. Rhonemus, Kern M. Storo, Christopher A. Tyler
  • Publication number: 20140349954
    Abstract: The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (I); a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 27, 2014
    Inventors: Gerd Kleefeld, Robrecht Froyman, Julia Charlotte Dörner, Carolin Ludwig, Satoshi Omura, Sunazuka Toshiaki, Hirose Tomoyasu, Sugawara Akihiro, Shiomi Kazuro
  • Publication number: 20140343263
    Abstract: The invention relates to a process for separating bioactive compounds obtained from vegetable materials. The invention also relates to a process for extracting bioactive compounds from vegetable material.
    Type: Application
    Filed: May 27, 2014
    Publication date: November 20, 2014
    Applicant: Langtech International Pty., Limited
    Inventors: Tim Lang, Wayne Simpkins
  • Patent number: 8865241
    Abstract: The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient Sphingans. The invention is also directed to a process for preparing a clarified Sphingan solution comprising heating aqueous Sphingan solution, in particular PHB-deficient Sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and/or clarified Sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 21, 2014
    Assignee: CP Kelco U.S., Inc.
    Inventors: Stan Bower, Ellen Burke, Nancy E. Harding, Yamini N. Patel, J. Carrie Schneider, Dagmar Meissner, Neil A. Morrison, Ralph Bezanson
  • Patent number: 8846851
    Abstract: A salt catalyst comprises an ionic complex of i) a nitrogen base comprising one or more guanidine and/or amidine functional groups, and ii) an oxoacid comprising one or more active acid groups, the active acid groups independently comprising a carbonyl group (C?O), sulfoxide group (S?O), and/or a phosphonyl group (P?O) bonded to one or more active hydroxy groups; wherein a ratio of moles of the active hydroxy groups to moles of the guanidine and/or amidine functional groups is greater than 0 and less than 2.0. The salt catalysts are capable of catalyzing ring opening polymerization of cyclic carbonyl compounds.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: September 30, 2014
    Assignee: International Business Machines Corporation
    Inventors: Daniel J. Coady, Kazuki Fukushima, James L. Hedrick, Hans W. Horn, Julia E. Rice
  • Publication number: 20140271474
    Abstract: Radiolabeled tracers for binding to sodium/glucose cotransporters (SGLTs), and their synthesis, are provided. The tracers are high-affinity inhibitors of SGLTs, glycosides labeled with radioactive halogens. Also provided are in vivo and in vitro techniques for using the tracers as analytical tools to study the biodistribution and regulation of SGLTs in health and disease, and to evaluate therapeutic interventions. The ability to monitor radiolabel tracer disposition in real time enables the design of new SGLT inhibitors with lower metabolism and higher efficiency.
    Type: Application
    Filed: June 14, 2012
    Publication date: September 18, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ernest M. Wright, Jorge R. Barrio
  • Patent number: 8835614
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: September 16, 2014
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Publication number: 20140256924
    Abstract: Carbohydrates are biomolecules that are involved in a range of biological processes and play key roles in, for instance, host immune response and cellular adhesion. Accordingly, functionalisation of medical devices such as stents, valves, catheters, prostheses and other devices for in vivoimplantation with carbohydrates is an area in which considerable interest is developing. Disclosed herein are surfaces having carbohydrates immobilised thereon. The carbohydrate has a linker moiety covalently bound thereto and the linker moiety has a carbon atom that forms a covalent bond with an atom on the target surface. The carbon based bond is a strong, non-hydrolysable covalent bond.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 11, 2014
    Applicant: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF
    Inventors: Eoin M. Scanlan, Paula E. Colavita, Deirdre Murphy, Jean Bourke
  • Publication number: 20140249301
    Abstract: The invention provides novel methods and compositions directed to farnesol production, accumulation and cellular sequestration in plants. More specifically, the methods of the invention comprise modifying plant cells that express farnesene to convert the farnesene to farnesol, and in some cases, to farnesol glycoside, such as farnesol glucoside. In other embodiments, carbon flux is shunted towards sesquiterpene production by applying certain plant growth regulators and herbicides to increase sesquiterpene production.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 4, 2014
    Applicant: Chromatin, Inc.
    Inventor: John C. Steffens
  • Publication number: 20140200336
    Abstract: A sensor for the detection or measurement of a carbohydrate analyte in fluid comprises components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of the analyte but not the assay components, the assay components comprising: a carbohydrate binding molecule labelled with one of a proximity based signal generating/modulating moiety pair; and a carbohydrate analogue capable of competing with the analyte for. binding to the carbohydrate binding molecule, the carbohydrate analogue being a flexible water-soluble polymer comprising: polymerized or co-polymerised residues of monomer units, the monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and pendant moieties which are the other of the proximity based signal generating/modulating moiety pair.
    Type: Application
    Filed: February 12, 2014
    Publication date: July 17, 2014
    Applicant: MEDTRONIC MINIMED, INC.
    Inventors: Jesper Svenning KRISTENSEN, Klaus GREGORIUS, Casper STRUVE, Yihua YU
  • Patent number: 8742094
    Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method, a cyclosaligenyl nucleotide is produced first, to which a linker is added, which is used to perform the immobilization on a solid phase. A subsequent reaction with corresponding nucleophiles results in the desired phosphate-bridged nucleoside conjugates, which can then again be cleaved from the solid phase-bound linker.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: June 3, 2014
    Assignee: Universitaet Hamburg
    Inventors: Chris Meier, Viktoria Caroline Tonn
  • Publication number: 20140142287
    Abstract: The present invention provides carbohydrate-based surfactants and methods for producing the same. Methods for producing carbohydrate-based surfactants include using a glycosylation promoter to link a carbohydrate or its derivative to a hydrophobic compound.
    Type: Application
    Filed: September 30, 2013
    Publication date: May 22, 2014
    Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Jeanne E. Pemberton, Robin L. Polt, Raina M. Maier, Clifford S. Coss
  • Patent number: 8710210
    Abstract: A method for synthesizing an oligonucleotide which comprises using a sulfurizing agent of general formula (I) for sulfurizing at least one phosphorus internucleotide linkage of a precursor of the oligonucleotide, wherein R is an aryl group or a heteroaryl group, which is bonded to the S-atom through an annular carbon atom; and R1 and R2 are independently organic residues, preferably a C1-C20 hydrocarbon residue. The method may further comprise purifying the oligonucleotide. Also included is a process for the synthesis of the sulfurizing agent.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: April 29, 2014
    Assignee: Girindus America, Inc.
    Inventors: Yigang He, Victor Sorokin, Wieslaw Adam Mazur
  • Patent number: 8703923
    Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 22, 2014
    Assignee: Reliable Biopharmaceutical Corporation
    Inventors: Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
  • Patent number: 8691517
    Abstract: A sensor for the detection or measurement of a carbohydrate analyte in fluid comprises components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of the analyte but not the assay components, the assay components comprising: a carbohydrate binding molecule labelled with one of a proximity based signal generating/modulating moiety pair; and a carbohydrate analogue capable of competing with the analyte for binding to the carbohydrate binding molecule, the carbohydrate analogue being a flexible water-soluble polymer comprising: polymerized or co-polymerised residues of monomer units, the monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and pendant moieties which are the other of the proximity based signal generating/modulating moiety pair.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: April 8, 2014
    Assignee: Medtronic Minimed, Inc.
    Inventors: Jesper Svenning Kristensen, Klaus Gregorius, Casper Struve, Yihua Yu
  • Patent number: 8680251
    Abstract: The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pharmaceutical formulation containing these compounds.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: March 25, 2014
    Assignee: Univerzita Palackeho V Olomouci
    Inventors: Jan {hacek over (S)}arek, Pavla Spá{hacek over (c)}ilová, Marian Hajduch
  • Patent number: 8653049
    Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: February 18, 2014
    Assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry AV CR, V.V.I., Vyzkumny USTAV Veterinarniho Lekarstvi, V.V.I.
    Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
  • Publication number: 20140046046
    Abstract: Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    Type: Application
    Filed: October 22, 2013
    Publication date: February 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Matthias ECKHARDT, Peter EICKELMANN, Frank HIMMELSBACH, Edward Leon BARSOUMIAN, Leo THOMAS
  • Patent number: 8614314
    Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: December 24, 2013
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Roy Sucharita, Takashi Kei Kishimoto, Ganesh Venkataraman
  • Publication number: 20130287708
    Abstract: Provided is an all natural composition including naturally-obtained plant extracts.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 31, 2013
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Y&B Mother's Choice Ltd.
    Inventors: Tova Silberstein, Rachel Lutz, Shlomo Magdassi, Barak Tzadok
  • Patent number: 8546549
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: October 1, 2013
    Assignee: Wyeth LLC
    Inventors: Keith Moran, Jianxin Gu
  • Patent number: 8541381
    Abstract: This invention describes a process for producing a fraction enriched with jujubogenin and psudojujubogenin lycosides from Bacopa species, wherein the total Bacopa saponin concentration is up to 100% when estimated by HPLC method of analysis. The present invention also describes the processes for the enrichment of new compositions and individual saponin compounds from Bacopa monnieri to more than 95% purity. It further describes an analytical HPLC method for the estimation of total Bacopa saponin fraction and its use in therapeutic applications. This invention also includes two Bacopa saponin 3-O-[?-D-glucopyranosyl-(1?3)-?-D-glucopyranosyl] jujubogenin and 3-O-[?-D-glucopyranosyl-(1?3)-?-D-glucopyranosyl] pseudojujubogenin herein referred to as bacopaside N1 of general formula (1) and bacopaside N2 of general formula (2) respectively.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: September 24, 2013
    Assignee: Laila Impex
    Inventors: Raju Gokaraju Ganga, Raju Gokaraju Rama, Subbaraju Gottumukkala Venkata, Trimurtulu Golakoti, Sivaramakrishna Chillara
  • Publication number: 20130203688
    Abstract: The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration residue in association with a pharmaceutically acceptable carrier. The present document also describes a nutraceutical or cosmeceutical composition for improving health condition of skin. The present document describes a method of producing a sugar plant syrup-derived product; wherein the improvement is characterized in the step of: collecting a sugar plant syrup residue during the production of sugar or syrup to produce a syrup-derived by-product.
    Type: Application
    Filed: August 19, 2011
    Publication date: August 8, 2013
    Applicant: FÉDÉRATION DES PRODUCTEURS ACÉRI-COLES DU QUÉBEC
    Inventors: Julie Barbeau, Geneviève Béland
  • Patent number: 8492125
    Abstract: The present invention relates to a method for dissolving cellulose. The method comprises—introducing cellulosic raw material,—treating the cellulosic raw material in an enzymatic treatment process,—mixing the cellulosic raw material after the enzymatic treatment in an aqueous solution in order to obtain an aqueous intermediate product containing the cellulosic raw material of at least 3.5 wt.-%, alkali metal hydroxide between 3.5 wt.-% and 7 wt.-% and zinc salt,—freezing the intermediate product to a solid state, and—melting the frozen intermediate product. The present invention also relates to a cellulosic product obtained from a solution comprising dissolved cellulose.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: July 23, 2013
    Assignee: TTY Saatio
    Inventors: Marianna Vehvilainen, Pertti Nousiainen, Taina Kamppuri, Maija Jarventausta
  • Patent number: 8470984
    Abstract: The present invention provides a process for the preparation of a morpholinyl anthracycline derivative in good yields and purity, including 3?-deamino-3?-4?-anhydro-[2?(S)-methoxy-3?(R)-hydroxy-4?-morpholinyl]doxorubicin (1).
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: June 25, 2013
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Michele Caruso, Vittoria Lupi, Matteo Salsa
  • Patent number: 8461312
    Abstract: The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: June 11, 2013
    Assignee: Sanofi
    Inventors: Guenter Billen, Wendelin Frick, John Patrick Larkin, Guy Lemaitre, Francoise Bendetti, Philippe Boffelli, Jean-Yves Godard, Christian Masson, Veronique Crocq, Sylvaine Lafont, Jos Hulshof
  • Patent number: 8436155
    Abstract: A 7,2?-dehydrate puerarin represented by formula (I) and salt derivatives thereof. The compounds are prepared from puerarin by intramolecular mitsunobu reaction. They are capable of shortening arrhythmia duration and prolonging coagulation time. They can be prepared into oral formulations or injections for treatment of cardiovascular and cerebrovascular diseases including arrhythmia, coronary heart disease, angina pectoris, myocardial infarction, and cerebral infarction.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: May 7, 2013
    Assignee: Shandong University
    Inventors: Hongxiang Lou, Jian Gao, Xia Xue
  • Patent number: 8436156
    Abstract: The present invention provides a method for producing sucralose from a feed stream resulting from the chlorination of a sucrose-6-acylate in a reaction vehicle. The feed stream includes a sucralose-6-acylate, the reaction vehicle, water, and salts. The salts include one or more selected from the group consisting of alkali metal chlorides, alkaline earth metal chlorides and ammonium chloride. The method includes: (i) deacylation of the sucralose-6-acylate by treatment with a base to afford a product stream comprising sucralose; (ii) partial removal of water and, optionally, reaction vehicle from the product stream of (i) in order to cause precipitation of the salts from the product stream; (iii) removal of the precipitated salts from the product stream of (ii); and (iv) isolation of sucralose from the product stream of (iii).
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: May 7, 2013
    Assignee: Tate & Lyle Technology Limited
    Inventors: John Kerr, Robert Jansen, Duane A. Leinhos, James Edwin Wiley, Jr., Sebastien Camborieux, Anthony Baiada, Gordon Walker, Carlo Maffezzoni
  • Patent number: 8436157
    Abstract: The present invention provides a method for producing sucralose from a feed stream including a sucrose-6-acylate in a reaction vehicle.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 7, 2013
    Assignee: Tate & Lyle Technology Limited
    Inventors: James Edwin Wiley, Jr., Duane A. Leinhos, David A. Dentel, John Kerr
  • Patent number: 8420790
    Abstract: The present invention relates to a process for the synthesis of the Factor Xa anticoagulent Fondaparinux and related compounds. The invention relates, in addition, to efficient and scalable processes for the synthesis of various intermediates useful in the synthesis of Fondaparinux and related compounds.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: April 16, 2013
    Assignee: Reliable Biopharmaceutical Corporation
    Inventors: Payal Parth Patel, Chun Ma, Kevin K. Ohrr, Sourena Nadji
  • Patent number: 8367635
    Abstract: Methods for the prevention and treatment of infection, preferably antibiotic resistant wound infection, using a paste formed by the reaction of sucralfate with an acid component are provided. Methods of preparing stable sucralfate compositions are disclosed. Compositions of and products containing the sucralfate paste are also described.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: February 5, 2013
    Inventor: Patrick D. McGrath
  • Patent number: 8357787
    Abstract: Chitosan-containing blends and methods of dissolving and using chitosan are disclosed. A blend includes a solid acid or a solid agent that generates a proton in situ in the presence of water mixed together with a dry solid chitosan, and may optionally contain other components. The blends are in a dry, free-flowing, particulate form. Methods of dissolving a blend typically comprise adding a quantity of the blend to a low volume of water and mixing until the chitosan and solid acid or solid agent are dissolved and then further diluting this mixture by the addition of water, or used as-is. Devices containing the blends are also described along with methods of using the devices, such as for controlled release of solubilized chitosan in a body of water, such as a stream, containing impurities (e.g., particles, sediment, or suspended matter or dissolved substances) to cause flocculation or precipitation of such impurities.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: January 22, 2013
    Assignee: HaloSource, Inc.
    Inventors: Everett J. Nichols, James R. Scott
  • Patent number: 8357785
    Abstract: A method for the aralkylation of anthracyclins by utilizing an aralkylating agent R3—CH2X (for example, BnBr) in accordance with the reaction pathway describe by the scheme shown in FIG. 1. The present invention recognizes that 4-R1, 3?-N3-Daunomycines are suitable substrates for selective 4?-O-benzylation, yielding 4-R1, 3?-N3-4?-O-Aralkyl-Daunorubicines (in particular, 4?-O-Bn-Daunomycines). Thus, the present invention provides a pathway for a simple production of 4?-O-aralkylated derivatives of anthracyclines which can be effectively used to produce anthracyclines.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: January 22, 2013
    Assignee: Solux Corporation
    Inventors: Alexander F. Zabudkin, Victor Matvienko, Alexey Matveev, Aleksandr M. Itkin
  • Patent number: 8357786
    Abstract: Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2?,3?,12?-trihydroxydammar-20(22)-E,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin A, and a novel compound 2?,3?,12?-trihydroxydammara-20,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin B.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: January 22, 2013
    Assignee: TG Biotech Co., Ltd.
    Inventors: Tae Lin Huh, He Bok Song, Ji Eun Kim, So Young Joon, Won Keun Oh